Genmab A/S (GMAB) Expected to Announce Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $905.7740 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Stock Up 1.6%

Shares of NASDAQ:GMAB traded up $0.44 during mid-day trading on Tuesday, hitting $27.48. 601,728 shares of the company traded hands, compared to its average volume of 1,689,363. The firm has a market cap of $17.13 billion, a P/E ratio of 17.73, a PEG ratio of 1.18 and a beta of 0.86. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. Genmab A/S has a 52-week low of $18.89 and a 52-week high of $35.43. The firm’s 50 day simple moving average is $27.43 and its 200 day simple moving average is $30.03.

Analyst Upgrades and Downgrades

GMAB has been the topic of several analyst reports. Guggenheim dropped their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Jefferies Financial Group initiated coverage on Genmab A/S in a report on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price on the stock. Finally, Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.07.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC grew its stake in Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. grew its stake in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. NewEdge Advisors LLC grew its stake in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. Brown Brothers Harriman & Co. grew its stake in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.